Skip to content

Clinical study of Sanleng fuzheng xiaoliu prescription on the influence of long-term survival and life quality of postoperative gastric cancer patients

Clinical study of Sanleng fuzheng xiaoliu prescription on the influence of long-term survival and life quality of postoperative gastric cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010674
Enrollment
Unknown
Registered
2017-02-18
Start date
2017-04-01
Completion date
Unknown
Last updated
2021-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

treatment group:Sanleng fuzhengxiaoliu

Sponsors

Yueyang Hosptail of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patiens with Stage IIa to IIIc gastric cancer to be accepted complete surgical resection, and the gastric cancer to be confirmed after operation; 2. patients with adjuvant chemotherapy after operation; 3. To be aged 18-80 years old; 4. Karnovfsky performance score more than 60 points; 5. normal liver and kidney function 6. patients with good compliance, can understand the situation of the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. combined with other serious diseases; 2. patients with other concurrent malignancy; 3. life expectancy of less than 6 months; 4. there are serious complications, such as active gastrointestinal bleeding, gastrointestinal perforation, obstruction, jaundice, non cancerous fever >38 c; 5. patients with pregnancy or lactation; 6. participants thought previous or current physical or mental condition of the patient may risk in the process of test, interference test evaluation or interfere with the patients to participate in the test; 7. in severe and difficult to control the local or systemic acute, chronic infection period; 8. patients participated in clinical medicine or instrument experimental research within 30 days; 9. patient use any other anti-cancer trial medicines at the same time or within 4 weeks; 10. the researchers considered unfit for test of the other situations: coronary heart disease and abnormal ECG; before entering the study myocardial infarction within 6 months; a history of major neurological or psychiatric disorders, including Dementia or epilepsy; activity of coagulation.

Design outcomes

Primary

MeasureTime frame
Survival period;Progression free survival;TCM syndrome score;

Secondary

MeasureTime frame
Quality of life index;

Countries

China

Contacts

Public ContactGuo Xiaodong

Yueyang Hosptail of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine

gxd_1996@hotmail.com+86 18918757286

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026